| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| 2025 | 2024 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 11 | NIH | 1/6/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,333,866 ) |
| 2024 | 2024 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 11 | NIH | 2/23/2024 | $1,852,814 |
| 2024 | 2024 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 003 | 11 | NIH | 9/11/2024 | $309,318 |
| 2024 | 2024 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 002 | 11 | NIH | 4/23/2024 | $171,734 |
| 2024 | 2023 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 10 | NIH | 1/23/2024 | $0 |
| 2024 | 2020 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 5 | NIH | 10/16/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,520,032 ) |
| 2023 | 2023 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 9 | NIH | 1/13/2023 | $25,675 |
| 2023 | 2023 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 10 | NIH | 3/24/2023 | $2,982,169 |
| 2023 | 2023 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 002 | 10 | NIH | 5/5/2023 | $135,000 |
| 2023 | 2023 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 003 | 10 | NIH | 8/23/2023 | $377,188 |
|
| Issue Date FY: 2022 ( Subtotal = $3,425,845 ) |
| 2022 | 2022 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 9 | NIH | 8/16/2022 | $1,710,561 |
| 2022 | 2022 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 9 | NIH | 4/1/2022 | $1,715,284 |
| 2022 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 5 | NIH | 2/3/2022 | $0 |
| 2022 | 2020 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | R03HD099617 | A Population-Based Study to Quantify the Risks of Opioid Analgesics in Pregnancy | 000 | 2 | NIH | 9/23/2022 | $0 |
| 2022 | 2018 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 001 | 3 | NIH | 9/26/2022 | -$53,938 |
| 2022 | 2017 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | R21AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 2 | NIH | 9/26/2022 | $53,938 |
| 2022 | 2017 | QUEENS UNIVERSITY AT KINGSTON | 99 UNVERSITY AVE | KINGSTON | ON | | | CAN | R21AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 001 | 2 | NIH | 9/28/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,940,337 ) |
| 2021 | 2021 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 002 | 8 | NIH | 9/17/2021 | $435,000 |
| 2021 | 2021 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 8 | NIH | 2/26/2021 | $2,631,187 |
| 2021 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 7 | NIH | 2/26/2021 | $0 |
| 2021 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | | | CAN | U01DK103271 | Expansion of the MAPP Research Network: Microbial and Biopsychosocial Contributio | 000 | 5 | NIH | 4/2/2021 | -$125,850 |
|
| Issue Date FY: 2020 ( Subtotal = $2,839,125 ) |
| 2020 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 7 | NIH | 2/28/2020 | $2,157,134 |
| 2020 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 7 | NIH | 9/3/2020 | $318,000 |
| 2020 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 001 | 5 | NIH | 1/27/2020 | $307,868 |
| 2020 | 2020 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R03HD099617 | A Population-Based Study to Quantify the Risks of Opioid Analgesics in Pregnancy | 000 | 2 | NIH | 8/10/2020 | $56,123 |
| 2020 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 4 | NIH | 1/24/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,190,269 ) |
| 2019 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 003 | 6 | NIH | 6/28/2019 | $2,567,173 |
| 2019 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 004 | 6 | NIH | 8/26/2019 | $265,124 |
| 2019 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 4 | NIH | 2/1/2019 | $308,233 |
| 2019 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R03HD099617 | A Population-Based Study to Quantify the Risks of Opioid Analgesics in Pregnancy | 000 | 1 | NIH | 9/12/2019 | $62,031 |
| 2019 | 2019 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 6 | NIH | 4/2/2019 | $1,554,881 |
| 2019 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 002 | 5 | NIH | 6/28/2019 | -$2,407,344 |
| 2019 | 2017 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 4 | NIH | 6/28/2019 | -$159,829 |
| 2019 | 2017 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R21AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 2 | NIH | 1/10/2019 | $0 |
| 2019 | 2017 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R21AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 001 | 2 | NIH | 2/1/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,954,895 ) (Continued on the next page) |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 002 | 3 | NIH | 4/5/2018 | -$311,503 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 002 | 3 | NIH | 4/5/2018 | $311,503 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 001 | 3 | NIH | 3/31/2018 | $53,938 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | R33AI121575 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics | 000 | 3 | NIH | 12/11/2017 | $311,503 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U01DK103271 | Expansion of the MAPP Research Network: Microbial and Biopsychosocial Contributio | 000 | 5 | NIH | 7/10/2018 | $236,048 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 001 | 5 | NIH | 9/11/2018 | $630,706 |
| 2018 | 2018 | QUEEN'S UNIVERSITY AT KINGSTON | 99 UNIVERSITY AVE | KINGSTON | ON | K7L 3N5 | | CAN | U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | 000 | 5 | NIH | 2/28/2018 | $1,776,638 |
|